seAFOOD.

Trial name or title	The seafood (systematic evaluation of aspirin and fish oil) polyp prevention trial
Methods	RCT
Participants	NHS Bowel Cancer Screening Programme patients (55‐73 years) identified as "high risk" (≥ 5 small adenomas; or ≥ 3 adenomas with at least one being ≥ 10 mm in diameter) after their 1st screening colonoscopy
Interventions	Each for 12 months: Arm 1: EPA (ALFA capsules: 2 x 500 mg/d = 2 g/d) and aspirin placebo (1/d) Arm 2: EPA placebo (capric and caprylic acid triglycerides: 2/d) and aspirin EC (1/d = 300 mg/d) Arm 3: EPA (ALFA capsules: 2 x 500 mg/d = 2 g/d) and aspirin EC (1/d = 300 mg/d) Arm 4: EPA placebo (capric and caprylic acid triglycerides: 2/d) and aspirin placebo (1/d)
Outcomes	Primary: number of participants with ≥ 1 adenomas at 12 months Secondary: adverse events, number of "advanced" adenomas per participant, number of "high risk" participants re‐classified as "intermediate risk", number participants with ≥ 1 advanced adenomas, adenoma region in the colorectum, total number of adenomas per participant, number of participants with colorectal cancer, levels of bioactive lipid mediators e.g. omega‐3
Starting date	Trial Registration entry: 6 May 2011 Trial start date: 30 May 2011 Estimated trial completion: 31 July 2017
Contact information	Mark Hull, Leeds Institute of Molecular Medicine, m.a.hull@leeds.ac.uk
Notes	ISRCTN05926847 EudraCT 2010‐020943‐10 www.seafood‐trial.co.uk